• Research Category Research & Development Services & Subcontracts
• Solicitation Number S26-141
• NCI OA Contract Number 75N91019D00024 – NCI-FFRDC

Description

Leidos Biomedical Research, Inc. seeks a qualified vendor to perform Food and Drug Administration (FDA) mandated safety analysis of influenza vaccines. For each vaccine under investigation, the vendor will perform a repeat-dose toxicology study in New Zealand White Rabbits. The studies in animals must be conducted in accordance with U.S. Good Laboratory Practices (GLP) standards (Title 21 of the US Code of the Federal Register section Part 58; 21CFR58). The study should be performed consistent with guidance in International Conference on Harmonization (ICH) M3(R2) and S6(R1) documents and other relevant guidance from FDA and ICH. The vendor shall perform testing according to standard operating procedures (SOP) and approved study protocol to measure the toxicity of the vaccines when delivered intramuscularly or intranasally. Toxicity is measured by multiple in-life parameters, gross pathology and histological analysis.
Anticipated products and respective subcontract periods are listed below:
Subcontract Period Product
Base Period BPL-1357B
Option Period 1 Additional BPL inactivated vaccine
Option Period 2 Neuraminidase (NA) protein subunit

Proposal Instructions

9/29/26: RFP Amendment 01 issued to extend the proposal due date to 12:00 p.m. (ET), Wednesday, October 21, 2026 and distribute responses to Offeror questions.

Offeror questions are due 12:00 P.M. (ET) TUESDAY, SEPTEMBER 22, 2026. A pre-offer submission teleconference will be held at 12:30 P.M. (ET) WEDNESDAY, SEPTEMBER 30, 2026. Offers are due 12:00 P.M. (ET) WEDNESDAY, OCTOBER 14, 2026. For the full solicitation package please contact Maureen Wilson at maureen.wilson2@nih.gov .